Cachexia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cachexia – Drugs In Development, 2024 report and make more profitable business decisions.
Cachexia, also known as wasting syndrome, is characterized by loss of skeletal muscle mass. Symptoms include involuntary unintentional weight loss, skeletal muscle wasting, and anorexia. Risk factors include HIV, cancer, chronic obstructive pulmonary disease, congestive heart failure, rheumatoid arthritis, and cystic fibrosis. Treatment includes appetite stimulants, exercise, and dietary supplements.
The Cachexia drugs in development market research report provide comprehensive information on the therapeutics under development for Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cachexia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cachexia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cachexia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cachexia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cachexia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acesis Holdings CorpAphios Corp
AstraZeneca Plc
Aventi Co Ltd
Catalym GmbH
Endevica Bio Inc
Epitracker Inc
Faraday Pharmaceuticals Inc
HEM Pharma Inc
Ildong Pharmaceutical Co Ltd
Imperial College London
Laekna Therapeutics Shanghai Co Ltd
MedAvail Holdings Inc
Metafines Co Ltd
Novo Nordisk AS
Oregon State University
Pephexia Therapeutics ApS
Senzer Ltd
Tvardi Therapeutics Inc
Vanderbilt University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cachexia reports